About BioVaria
BioVaria is an accelerator and incubator program based in Munich, Germany. With a presence in 16 countries, it has supported around 82 startups in sectors like Life Sciences, Enterprise Applications. As of Oct 2026, BioVaria has witnessed 17 portfolio exits. Most notable companies in
its portfolio include AbbVie, WuXi AppTec and Catalent. The program is backed by a team of 10 people who primarily support Grant (prize money) startups based in Germany. Its latest investment was a Undisclosed Grant (prize money) round in iSD Immunotech on May 19, 2019.
Key Metrics
Location
Munich, Germany
Portfolio Companies
Sectors of Investment
Stages of Investment
Grant (prize money) & Seed
BioVaria's List of Top Investments
BioVaria has a portfolio of 82 companies. Their most notable investments include AbbVie and WuXi AppTec.Their portfolio spans across Germany, Austria, Switzerland and 13 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 7 other sectors, across stages such as Grant (prize money), Seed stages. Here is the list of top investments by BioVaria:1. AbbVie
AbbVie is a global, research-based biopharmaceutical company. It has developed adalimumab, which is marketed under the trade name Humira, a biopharmaceutical treatment for autoimmune diseases. It also develops medicines includes AndroGel, Creon, Duodopa and Duopa, Kaletra, Lupron, Niaspan, Norvir, Sevoflurane. In 2022, the company recorded annual revenues of $56.74B and a net profit of $7.54B.
Key facts about AbbVie
- Founded Year: 2012
- Location: Chicago (United States)
- Annual Revenue: $1B+ as on Dec 31, 2014
- Stage: Public
- Total Funding till date: $14.7B
- Employee Count: 60,010 as on Aug 31, 2026
- Investors: Berkshire Hathaway, Alcor Fund and 10 Others
- Latest Funding Round: Conventional Debt, Oct 03, 2018, $*****
- Highlight: Public
2. WuXi AppTec
WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of $5.84B and a net profit of $1.31B.
Key facts about WuXi AppTec
- Founded Year: 2000
- Location: Shanghai (China)
- Annual Revenue: £10M - £50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $40M
- Employee Count: 4,155 as on Nov 16, 2025
- Investors: Strait Huifu Industrial Investment Fund Management, HPR Capital and 27 Others
- Latest Funding Round: Post IPO, Apr 02, 2021, $*****
- Highlight: Public
3. Catalent
Provider of development, manufacturing, and packaging solutions for medicines and supplements. It offers services for oral dose forms, biologics, and specialty technologies. These services include formulation, bioavailability enhancement, and analytical solutions. The company also provides clinical supply forecasting, packaging, and distribution.
Key facts about Catalent
- Founded Year: 2007
- Location: Somerset (United States)
- Annual Revenue: $1B+ as on Jun 30, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 12,602 as on Mar 31, 2026
- Investors: Aisling Capital, JPMorgan Chase and 4 Others
- Latest Funding Round: Grant (prize money), Oct 01, 2020, $*****
- Highlight: Acquired
4. Pfizer
Provider of pharmaceutical products for multiple disease treatments. It has developed a novel cancer medicine that works by inhibiting blood supply in tumor cells and destroys cellular reproduction. The other product includes Chantix that helps smokers to quit smoking.In 2022, the company recorded annual revenues of $92.95B and a net profit of $29.04B.
Key facts about Pfizer
- Founded Year: 1849
- Location: New York City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Employee Count: 109,179 as on Aug 31, 2026
- Investors: Berkshire Hathaway, Alcor Fund and 16 Others
- Latest Funding Round: Grant (prize money), Jun 27, 2023, $*****
- Highlight: Public
5. Immatics
Developer of T -cell-based immunotherapies for the treatment of cancer. The company has propriety platform XPRESIDENT is involved in identifying and validating antigens specific to cancer cells and subsequently develops adoptive cell therapies and bispecific TCRs for treating cancer. IMA101, using its proprietary ACTolog approach, which is T-cell products generated from peripheral blood cells with defined target selectivity.
Key facts about Immatics
- Founded Year: 2000
- Location: Tubingen (Germany)
- Stage: Public
- Total Funding till date: $236M
- Employee Count: 652 as on Aug 31, 2026
- Investors: Amgen Business Development, Timefolio Capital and 19 Others
- Latest Funding Round: Post IPO, Jul 24, 2023, $*****
- Highlight: Public
BioVaria's Year-on-Year Investment Trends
BioVaria has invested in 82 companies over the last 15 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in iSD Immunotech.BioVaria's Investments by Stage
BioVaria has made 3 investments in Grant (prize money) stage with an average round size of $1.43K and 1 investment in Seed stage.Stage of entry | No. of Investments |
|---|---|
Grant (prize money) | 3 |
Seed | 1 |
Note: We have considered here, only first round of investments
BioVaria's Investments by Sector
BioVaria has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications and HealthTech. Notably, it has invested in 54 Enterprise (B2B) companies, 51 Tech companies, 13 Software companies and at least 10 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 3 |
Enterprise Applications | 1 |
HealthTech | 1 |
Note: We have considered here, only first round of investments
BioVaria's Investments by Geography
BioVaria has made most investments in Germany (2), followed by Denmark where it has made 1 investment.Country | No. of Investments |
|---|---|
Germany | 2 |
Denmark | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
BioVaria's recent investments
BioVaria has not made any investment in 2026 so far.Here are the most recent investments by BioVaria:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 19, 2019 | Denmark | Grant (prize money) | 9551 | - | |
May 14, 2019 | Germany | Grant (prize money) | 8062 | - | |
May 24, 2018 | United Kingdom | Seed | 4741 | [+2] | |
May 30, 2011 | Germany | Grant (prize money) | 7845 | - |
IPOs and Publicly Listed companies in BioVaria's Portfolio
7 of BioVaria's portfolio companies have become public. Selvita got listed on the Warsaw Stock Exchange (WSE), in Mar 2021 and Immatics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are BioVaria's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 16, 2021 | - | - | 1757 | |
Jul 02, 2020 | - | - | 8845 | |
Dec 14, 2018 | - | - | 7325 | |
Dec 14, 2012 | - | - | 6645 | |
Sep 28, 2005 | - | - | 8116 |
Acquired companies in BioVaria's Portfolio
10 companies from BioVaria's portfolio have been acquired. The most recent acquisition was AVVie in Aug 2026 by P&F Products and Features for $*****.Here are BioVaria's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 05, 2026 | - | - | 9759 | |
Jun 01, 2026 | - | - | 3241 | |
Apr 07, 2026 | - | - | 2593 | |
Oct 02, 2024 | May 30, 2011 | Grant (prize money) | 5440 | |
Feb 06, 2024 | - | - | 8402 |
_1586343560242.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of BioVaria
BioVaria has a team of 10 members. BioVaria's team does not sit on the board of any company as of now.Co-investors of BioVaria
Over the past 15 years, 17 investors have co-invested in BioVaria's portfolio companies. This includes funds and angels.
- Top Co-investors of BioVaria: 3 investors entered a company along with BioVaria. These include investors like MassChallenge (1 company).
- Invested after BioVaria: A total of 14 investors have invested in BioVaria's portfolio after their investments. Top Investors include EIT Health (1 company) and Ukri (1 company).
